153 related articles for article (PubMed ID: 31318970)
1. The Prognosis of Stage IA Mixed Endometrial Carcinoma.
Li W; Li L; Wu M; Lang J; Bi Y
Am J Clin Pathol; 2019 Oct; 152(5):616-624. PubMed ID: 31318970
[TBL] [Abstract][Full Text] [Related]
2. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey.
Lajer H; Elnegaard S; Christensen RD; Ortoft G; Schledermann DE; Mogensen O
Acta Obstet Gynecol Scand; 2012 Aug; 91(8):976-82. PubMed ID: 22548255
[TBL] [Abstract][Full Text] [Related]
3. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
4. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
5. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
6. Incidence and clinical outcomes of non-endometrioid carcinoma of endometrium: Siriraj Hospital experience.
Jaishuen A; Kunakornporamat K; Viriyapak B; Benjapibal M; Chaopotong P; Petsuksiri J; Therasakvichya S
Asian Pac J Cancer Prev; 2014; 15(6):2905-9. PubMed ID: 24761923
[TBL] [Abstract][Full Text] [Related]
7. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
8. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
9. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
Bristow RE; Zahurak ML; Alexander CJ; Zellars RC; Montz FJ
Int J Gynecol Cancer; 2003; 13(5):664-72. PubMed ID: 14675352
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas.
Zhan X; Li L; Wu M; Lang J
Arch Gynecol Obstet; 2019 Oct; 300(4):1045-1052. PubMed ID: 31520260
[TBL] [Abstract][Full Text] [Related]
11. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
12. Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.
Scarfone G; Secomandi R; Parazzini F; Viganò R; Mangili G; Frigerio L; Villa A; Tateo S; Ricci E; Bolis G
Arch Gynecol Obstet; 2013 Feb; 287(2):351-6. PubMed ID: 23100038
[TBL] [Abstract][Full Text] [Related]
13. Effects of surgical volumes on the survival of endometrial carcinoma.
Becker JH; Ezendam NP; Boll D; van der Aa M; Pijnenborg JM
Gynecol Oncol; 2015 Nov; 139(2):306-11. PubMed ID: 26348315
[No Abstract] [Full Text] [Related]
14. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of lymphovascular space invasion and nodal involvement in intermediate- and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy.
Narayan K; Khaw P; Bernshaw D; Mileshkin L; Kondalsamy-Chennakesavan S
Int J Gynecol Cancer; 2012 Feb; 22(2):260-6. PubMed ID: 22080878
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.
Soslow RA; Bissonnette JP; Wilton A; Ferguson SE; Alektiar KM; Duska LR; Oliva E
Am J Surg Pathol; 2007 Jul; 31(7):979-87. PubMed ID: 17592263
[TBL] [Abstract][Full Text] [Related]
17. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.
Matthews RP; Hutchinson-Colas J; Maiman M; Fruchter RG; Gates EJ; Gibbon D; Remy JC; Sedlis A
Gynecol Oncol; 1997 May; 65(2):206-12. PubMed ID: 9159326
[TBL] [Abstract][Full Text] [Related]
18. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
[TBL] [Abstract][Full Text] [Related]
19. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract][Full Text] [Related]
20. Pathological findings in early-stage endometrial cancer.
Zehavi S; Schneider D; Bukovsky I; Halperin R
Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]